Annual Report 2020

Department of Proteomics

Tadashi Kondo, Mari Masuda

Introduction

 The Department of Proteomics was established in August 2020. We aim to discover seeds for novel biomarkers and therapeutic targets for cancer treatment by the proteomic approach.

The Team and What We Do

 We are particularly interested in proteins associated with clinical events such as metastasis, invasion, and resistance against cancer therapy by collaborating with domestic and overseas scientists who share the same research goal with us. In addition, we are members of the International Cancer Proteogenome Consortium (ICPC) and are responsible for the analysis of rare cancers in the ICPC's International Proteogenomic Project.

Research activities

 With the use of our in-house RPPA platform, we have identified the signals activated in the microenvironment of gastric cancer and liver metastasis of pancreatic cancer, respectively, in collaboration with Kumamoto University and the Exploratory Oncology Research & Clinical Trial Center (EPOC) of the NCC.

Future Prospects

 The goal of the Department of Proteomics is to provide high-quality proteomic analyses not only to the NCC colleagues but also to collaborators in a wide range of organizations and companies in Japan and abroad, and to contribute to better cancer treatment by discovering biomarkers and therapeutic targets through proteomic approaches.